drugset / Trial / NCT00109590

Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth

NCT00109590

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine which of 3 different anti-HIV drug regimens given to HIV infected pregnant women during and after their pregnancies is most effective in reducing the incidence of nevirapine (NVP) resistance mutations. Blood levels of NVP and lopinavir/ritonavir (LPV/r) will also be studied. Study hypothesis: NVP resistance following single-dose NVP can be prevented with the concomitant administration of additional antiretroviral therapy (ART).

Timeline

Start
2006-06
Primary completion
2008-10
Completion
2009-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Didanosine Small molecule 250 mg Oral
Subject Didanosine Small molecule 400 mg Oral
Subject Lopinavir Other / unclassified 400 mg Oral
Subject Nevirapine Small molecule 200 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral
Subject Zidovudine Small molecule 300 mg Oral